menu search

Centessa pharmaceuticals to present additional 52-weeks of continuous treatment data from third year of ongoing phase 2a study of serpinpc for the treatment of hemophilia at american society of hemato

BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-w...

November 2, 2023, 9:09 am

Centessa pharmaceuticals to present additional 52-weeks of continuous treatment data from third year of ongoing phase 2a study of serpinpc for the treatment of hemophilia at american society of hemato

BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-w...

November 2, 2023, 9:09 am

Week in review: everest acquires novel autoimmune therapy in $132 million agreement

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a...

September 24, 2023, 10:33 pm

Bicycle (bcyc) to begin pivotal bladder cancer study, stock up

Bicycle (BCYC) aligns with the FDA on the design of a mid-late-stage registrational study for its bladd...

September 12, 2023, 9:05 am

Akari therapeutics announces establishment of boston u.s. headquarters office to support expanding operations and start of registrational phase 3 clinical trials

NEW YORK and LONDON, Aug. 18, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

August 18, 2023, 12:00 pm

The prognosis for pds biotechnology

PDS Biotechnology Corporation has had a volatile stock performance in recent years. The company has made slow and steady progress advancing its pipeli...

August 13, 2023, 5:30 am

Why argenx stock is on fire today

Argenx's flagship autoimmune drug hit the primary endpoint in a registrational trial for a progressive ...

July 17, 2023, 1:02 pm

Correction — day one announces tovorafenib (day101) data and additional abstracts to be presented at the 2023 american society of clinical oncology (asco) annual meeting

BRISBANE, Calif., May 25, 2023 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by Day One Biopharmaceuticals, Inc. (Nas...

May 26, 2023, 12:30 am

Bridgebio pharma reports first quarter 2023 financial results and business update

– Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (A...

May 4, 2023, 11:30 am

Day one announces abstracts accepted for presentation at the 2023 american society of clinical oncology (asco) annual meeting

New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Trial-in-p...

April 26, 2023, 1:31 pm

Ocuphire pharma's shares fall despite positive data from registrational phase 3 trial of nyxol

Ocuphire Pharma Inc (NASDAQ: OCUP) announced topline results from the second Phase 3 MIRA-3 trial of Nyxol to reverse pharmacologically-induced myd...

March 29, 2022, 11:46 am

Nektar (nktr) q4 earnings top, three bempeg filings due in 2022

Nektar (NKTR) reports mixed fourth-quarter 2021 results. The company remains on track to report top-line data from three ...

March 1, 2022, 11:30 am

Nektar (nktr) q4 earnings top, three bempeg filings due in 2022

Nektar (NKTR) reports mixed fourth-quarter 2021 results. The company remains on track to report top-line data from three ...

March 1, 2022, 11:30 am

Nektar (nktr) q4 earnings top, three bempeg filings due in 2022

Nektar (NKTR) reports mixed fourth-quarter 2021 results. The company remains on track to report top-line data from three ...

March 1, 2022, 11:30 am


Search within

Pages Search Results: